Trial · NCT01659866
Antibiotic Prophylaxis for Transrectal Prostate Biopsy
NCT01659866, Phase 4, Completed, Northwestern University; results first posted 2019-06-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Antibiotic Prophylaxis for Transrectal Prostate Biopsy. Trials, record NCT01659866. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01659866
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Antibiotic Prophylaxis for Transrectal Prostate Biopsy
- NCT number
- NCT01659866
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 563 participants, actual
- Lead sponsor
- Northwestern University
- Conditions
- Infection
- Interventions
- Ciprofloxacin, trimethoprim-sulfamethoxazole, cefuroxime, ceftriaxone, gentamicin, amikacin, aztreonam, imipenem, ceftriaxone, gentamicin, amikacin, aztreonam, imipenem
- First posted
- 2012-08-08
- Last updated
- 2019-06-25
- Results first posted
- 2019-06-25
- Limitations and caveats
- Did not reach recruiting targets due to fewer prostate biopsies being performed than originally estimated in the study period.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Post-biopsy Infection. | 30 days post-biopsy | To measure and compare the rates of infection following TRUSP in subjects with and without CR-GNB. This measure is number of participants with post-biopsy infection. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Post-biopsy Infection. | 30 days post-biopsy | Of the 563 patients who signed consent, 53 were excluded; thus, 510 patients participated in the study. Of these 510, 430 harbored ciprofloxacin-susceptible flora and 80 harbored ciprofloxacin-resistant flora. | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Post-biopsy Infection. | Cipro-susceptible | 6 | participants | ||
| Number of Participants With Post-biopsy Infection. | Cipro-resistant | 3 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cipro-susceptible | 430 | |
| Overall Study | STARTED | Cipro-resistant | 80 | |
| Overall Study | COMPLETED | Cipro-susceptible | 430 | |
| Overall Study | COMPLETED | Cipro-resistant | 80 | |
| Overall Study | NOT COMPLETED | Cipro-susceptible | 0 | |
| Overall Study | NOT COMPLETED | Cipro-resistant | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cipro-susceptible | 0 | 430 |
| Total, all-cause mortality | Cipro-resistant | 0 | 80 |
| Total, other adverse events | Cipro-susceptible | 0 | 430 |
| Total, other adverse events | Cipro-resistant | 0 | 80 |
| Total, serious adverse events | Cipro-susceptible | 0 | 430 |
| Total, serious adverse events | Cipro-resistant | 0 | 80 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 28592230 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Cipro-susceptible vs Cipro-resistant: Number of Participants With Post-biopsy Infection. | Trial comparisons |
| Cipro-susceptible vs Cipro-resistant: deaths from any cause | Trial comparisons |
| Cipro-susceptible vs Cipro-resistant: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01659866
GET https://conductscience.org/api/trials/v1/NCT01659866/registered